Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8592514 | 0.95 | SIRT1 (0.57) | SIRT1SIRT2SIRT3RECQLKDM4E | |
| SCHEMBL8595169 | 0.87 | SIRT1 (0.50) | SIRT1SIRT2KDM4EALDH1A1CASP1 | |
| SCHEMBL11848642 | 0.82 | KDM4E (0.50) | SIRT1SIRT2KDM4EALDH1A1 | |
| SCHEMBL8257983 | 0.81 | SIRT1 (0.66) | SIRT1SIRT2SIRT3RECQLSMN1; SMN2 | |
| SCHEMBL8575677 | 0.81 | SIRT1 (0.46) | SIRT1SIRT2CASP1 | |
| SCHEMBL11844570 | 0.79 | SIRT2 (0.43) | SIRT1SIRT2KDM4EALDH1A1CASP1 | |
| SCHEMBL901479 | 0.79 | TSPO (0.55) | SIRT1SIRT2SMN1; SMN2 | |
| SCHEMBL30849292 | 0.78 | ADRA2A (0.49) | SIRT1SIRT2RECQLKDM4EALDH1A1 | |
| SCHEMBL11835576 | 0.77 | GABRA1 (0.44) | SIRT1SIRT2CASP1SIGMAR1 | |
| SCHEMBL8574636 | 0.77 | SIRT2 (0.42) | SIRT1SIRT2KDM4EALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043991-A4 | TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | claimed |
| JP-2001522884-A | — | — | 2001-11-20 | — | — | JP | claimed |
| EP-1043991-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-18 | — | — | EP | claimed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | claimed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1997000069-A1 | MELATONIN AGONISTS FOR TREATING BENIGN PROSTATIC HYPERPLASIA | ELI LILLY AND COMPANY (US) | 1997-01-03 | — | — | WO | claimed |
| EP-0748627-A2 | Melatonin agonists for use in the treatment of benign prostatic hyperplasia | ELI LILLY AND COMPANY (US) | 1996-12-18 | — | — | EP | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-0950657-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998055115-A1 | CARBOXAMIDES USEFUL AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997000069-A1 | MELATONIN AGONISTS FOR TREATING BENIGN PROSTATIC HYPERPLASIA | ELI LILLY AND COMPANY (US) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | SIRT1 3678/4885SIRT2 2715/4885SIRT3 4333/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | SIRT1 3680/4885SIRT2 3802/4885SIRT3 4222/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | SIRT1 2493/4885SIRT2 987/4885SIRT3 1660/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | SIRT1 2410/4885SIRT2 791/4885SIRT3 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.